secwatch.observer — SEC 8-K summary
======================================

Issuer:     Akebia Therapeutics, Inc. (AKBA)
CIK:        0001517022
Form:       8-K
Filed at:   2023-10-25T23:59:59+00:00
Accession:  0001517022-23-000037
Event type: regulatory
Sentiment:  positive
Materiality: 0.85
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

FDA accepts Akebia's resubmitted NDA for vadadustat; PDUFA date March 27, 2024
------------------------------------------------------------------------------

- Resubmission classified as class 2 response; six-month review period from resubmission date.
- Post-marketing safety data from tens of thousands of Japanese patients included in the filing.
- Vadadustat currently approved in 35 countries; Akebia preparing for commercial launch in H2 2024 if approved.
- PDUFA goal date of March 27, 2024; resubmission addressed issues from prior complete response letter.
- CEO expects availability shortly after approval, offering an oral alternative for anemia in dialysis patients.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1517022/000151702223000037/0001517022-23-000037-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1517022/000151702223000037/akba-20231025.htm
  HTML page:      https://secwatch.observer/filing/0001517022-23-000037

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer